sti-1558
Small moleculeexperimentalCOVID-19
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 7, 2022 (NCT05364840)
Timeline
Indications
Studied for
Mechanism of action
- Replicase polyprotein 1abANTAGONIST
Replicase polyprotein 1ab antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06044233 | Phase 1 | Sep 28, 2023 | Acea Bio, Zhejiang University |
| NCT05754411 | Phase 1 | May 15, 2023 | Acea Bio |
| NCT05716425 | Phase 3 | Feb 8, 2023 | Acea Bio |
| NCT05685719 | Phase 1 | Jan 4, 2023 | Acea Bio |
| NCT05523739 | Phase 1 | Sep 16, 2022 | Acea Bio |
| NCT05364840 | Phase 1 | Jun 7, 2022 | Sorrento Therapeutics, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acea Bio | For profit | 5 | 5 | 2 | 2022 |
| Sorrento Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1